troglitazone has been researched along with Hypereosinophilic Syndrome in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a human eosinophilic leukemia cell line, EoL-1, cell proliferation was suppressed by 2-day treatment with troglitazone." | 1.30 | Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor. ( Kiriyama, Y; Nochi, H; Sakurada, Y; Sugimura, A; Tamoto, K; Tokumitsu, Y; Tsuchiya, H; Ui, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugimura, A | 1 |
| Kiriyama, Y | 1 |
| Nochi, H | 1 |
| Tsuchiya, H | 1 |
| Tamoto, K | 1 |
| Sakurada, Y | 1 |
| Ui, M | 1 |
| Tokumitsu, Y | 1 |
1 other study available for troglitazone and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
Troglitazone suppresses cell growth of myeloid leukemia cell lines by induction of p21WAF1/CIP1 cyclin-dependent kinase inhibitor.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Chromans; Cyclin-Dependent Kinase Inhibitor p21; C | 1999 |